Thrombin time and anti-IIa dabigatran's activity: hypothesis of thrombin time's predictive value.
Dabigatran etexilate (Pradaxa®) is a new oral anticoagulant, competitive inhibitor, selective, fast, direct and reversible of thrombin. Dabigatran has an impact on a large panel of used coagulation tests. There is no relationship between thrombin time's lengthening and anti-IIa activity. This study defines thrombin time's predictive value, when its time is normal. The result of negative value is 97,6%. 255 patients were studied between January 2013 and July 2014. Thrombin time and anti-IIa activity were dosed for each patient. This study can be an assistant for therapeutic decision for laboratories without specialized test.
Laboratoire d'hématologie et immunologie, Centre Hospitalier, Le Mans, France.
Maïlys
M
Le Guyader
Laboratoire d'hématologie et immunologie, Centre Hospitalier, Le Mans, France.
Mohammed
M
Kaabar
Laboratoire d'hématologie et immunologie, Centre Hospitalier, Le Mans, France.
Pierre
P
Lemaire
Laboratoire d'hématologie et immunologie, Centre Hospitalier, Le Mans, France.
Fabienne
F
Pineau Vincent
D000991:Antithrombins / Q000494:pharmacology*; D000069604:Dabigatran / Q000494:pharmacology*; D006801:Humans; D011237:Predictive Value of Tests; D013918:Thrombin Time
D000991:Antithrombins; D000069604:Dabigatran
Pradaxa; anti-IIa activity; dabigatran; thrombin time